Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates

Group 1: Earnings Performance - Journey Medical Corporation reported quarterly earnings of $0.08 per share, surpassing the Zacks Consensus Estimate of a loss of$ 0.22 per share, and improving from a loss of $0.12 per share a year ago, representing an earnings surprise of 136.36% [1] - Over the last four quarters, the company has exceeded consensus EPS estimates two times [2] - The company posted revenues of$ 13.62 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 1.84%, and down from $15.26 million year-over-year [2] Group 2: Stock Performance and Outlook - Journey Medical shares have increased approximately 65.7% since the beginning of the year, while the S&P 500 has declined by 1.8% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$ 0.05 on revenues of $10.39 million, and for the current fiscal year, it is$ 0.15 on revenues of $74.53 million [7] Group 3: Industry Context - The Medical - Drugs industry, to which Journey Medical belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]